Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 70.90$. Average daily volumn in 3 months 8.25M. Market cap 142.10B

Stock symbol : BMY. Exchange : NYSE. Currency : USD
Lastest price : 67.71$. Total volume : 1.21M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Bristol-Myers Squibb Company (BMY)
Last Price

Previous Close67.24
Day Range67.39-67.80
Bid67.60 x 900
Ask67.61 x 800
Average Volume8.25M
Market Cap142.1B
52 Week Range65.28-81.44
Trailing P/E22.95
Foward P/E8.26
Dividend (Yield %)3.39%
Ex-Dividend Date2023-01-05

Financial Details

According to Bristol-Myers Squibb Company's financial reports the company's revenue in 2022 were 46.16B an decrease(0%) over the years 2021 revenue that were of 46.38B. In 2022 the company's total earnings were 6.33B while total earnings in 2021 were 6.99B(0%).

Loading ...


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myelom... a; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Market Cap:
Total Assets:
Total Cash:

News about "Bristol-Myers Squibb Company"


Should You Invest in Bristol-Myers Squibb Company (BMY) Now?

Source from : newsheater - 10 hours ago

Bristol-Myers Squibb Company (NYSE: BMY) has a higher price-to-earnings ratio of 22.78x compared to its average ratio,, and the 36-month beta value for BMY is at 0.44. Analysts have varying views on ...See details»


Bristol-Myers Squibb (NYSE:BMY) Seems To Use Debt Quite Sensibly

Source from : YAHOO!Finance - 1 days ago

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...See details»

A history of Bristol-Myers Squibb

Source from : pharmaphorum - 1 month ago

Squibb founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers invested $5000 into a struggling drug manufacturing firm in Clinton ...See details»


Bristol Myers Squibb Co. stock outperforms market on strong trading day

Source from : MarketWatch - 6 days ago

Shares of Bristol Myers Squibb Co. advanced 1.52% to $67.48 Wednesday, on what proved to be an all-around grim trading session for the stock market, with ...See details»

Bristol Myers Squibb Company

Source from : BN Americas - 2 years ago

Company: Processing Solutions Inc. Company: Citibank Latin America Citibank Latin America is the regional unit of multinational financial services company Citibank. The regional division was ...See details»

Bristol-Myers Squibb Company (NYSE: BMY) Down -0.67%: This Is What Analysts Are Now Forecasting

Source from : stocksregister - 5 days ago

Bristol-Myers Squibb Company (NYSE:BMY) price on Thursday, March 16, fall -0.67% below its previous dayโ€™s close as a downside momentum from buyers pushed the stockโ€™s value to $67.03. A look at the ...See details»

Bristol-Myers Squibb Company (NYSE:BMY) insiders sold US$39m worth of stock suggesting impending weakness.

Source from : Yahoo - 19 days ago

Many Bristol-Myers Squibb Company (NYSE:BMY) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions ...See details»

Bristol Myers Squibb Co.

Source from : Wall Street Journal - 7 days ago

1 Day BMY 0.44% DJIA -0.28% S&P 500 -0.15% Health Care/Life Sciences -0.58% Giovanni Caforio Chairman & Chief Executive Officer Stryker Corp., Bristol Myers Squibb Co., European Federation of ...See details»

Bristol-Myers Squibb Company (BMY) Stock: A Look at the Analyst Recommendations

Source from : newsheater - 7 days ago

Bristol-Myers Squibb Company (NYSE: BMY) has a higher price-to-earnings ratio of 22.36x compared to its average ratio. compared to its average ratio and a 36-month beta value of 0.44. Analysts have ...See details»

Bristol-Myers Squibb Company (NYSE:BMY) Q4 2022 Earnings Call Transcript

Source from : Yahoo News - 1 month ago

Bristol-Myers Squibb Company (NYSE:BMY) Q4 2022 Earnings Call Transcript February 2, 2023 Operator: Good morning. My name is Dennis, and I will be your conference operator today. At this time, I would ...See details»

Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments

Source from : Yahoo Finance - 5 days ago

In 2020, Bristol Myers Squibb (BMS) and the Bristol Myers Squibb ... This is against the companyโ€™s original goal to reach $1 billion in spending globally with diverse-owned businesses by 2025.See details»

Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference

Source from : Joplin Globe - 1 month ago

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.See details»

BMY Bristol-Myers Squibb Company

Source from : Seeking Alpha - 4 days ago

The chart has 1 X axis displaying Time. Data ranges from 2022-03-16 00:00:00 to 2023-03-17 18:18:25. The chart has 1 Y axis displaying values. Data ranges from -17.92 to 15.05.See details»

Bristol-Myers Squibb Co

Source from : Reuters - 15 days ago

2022 Businesscategory Bristol Myers Q3 sales fall on Revlimid, forex pressure, article with image October 25, 2022 Future of Healthcategory Johnson & Johnson's blood cancer therapy gets U.S. FDA ...See details»